Summary by Moomoo AI
CanSino Biologics announced that its developed Hib vaccine demonstrated 95% efficacy in clinical trials. The company is led by CEO Xuefeng YU and supported by Shou Bai CHAO. CanSino Biologics plans to complete all relevant clinical trial phases by November 15, 2024.